Search Results - G. Verhoef

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern

    Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern by José Luis Ferreiro, Julie Morscio, Daan Dierickx, Lukas Marcelis, G. Verhoef, Peter Vandenberghe, Thomas Tousseyn, Iwona Wlodarska

    Published 2015
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  2. 2
    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features

    EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features by José Luis Ferreiro, Julie Morscio, Daan Dierickx, Peter Vandenberghe, Olivier Gheysens, G. Verhoef, M. Zamani, Thomas Tousseyn, Iwona Włodarska

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study

    Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study by Johan Maertens, Koen Theunissen, G. Verhoef, Johny Verschakelen, Katrien Lagrou, Eric Verbeken, A. Wilmer, Jan Verhaegen, M. Boogaerts, Johan Van Eldere

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes

    Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes by Michel Delforge, H Demuynck, Peter Vandenberghe, G. Verhoef, Pierre Zachée, V. Van Duppen, P Marijnen, Herman Van den Berghe, MA Boogaerts

    Published 1995
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

    Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma by Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Peter Vandenberghe, José Thomas, Tjibbe de Groot, Jan Balzarini, C. De Wolf‐Peeters, L. Mortelmans, G. Verhoef

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response

    T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response by Peter Van Loo, Thomas Tousseyn, Vera Vanhentenrijk, Daan Dierickx, Agnieszka Małecka, Isabelle Vanden Bempt, G. Verhoef, Jan Delabie, Peter Marynen, Patrick Matthys, Chris De Wolf‐Peeters

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Rituximab in auto‐immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study

    Rituximab in auto‐immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study by Daan Dierickx, G. Verhoef, Ambro van Hoof, Philippe Mineur, Annelieke M. Roest, A. Triffet, Alain Kentos, P. Pierre, Dominique Boulet, G. Bries, Phu-Quoc Lê, Ann Janssens, André Delannoy

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Randomized Trial of a Shared Decision-Making Intervention Consisting of Trade-Offs and Individualized Treatment Information for <i>BRCA1/2</i> Mutation Carriers

    Randomized Trial of a Shared Decision-Making Intervention Consisting of Trade-Offs and Individualized Treatment Information for <i>BRCA1/2</i> Mutation Carriers by Mariëlle S. van Roosmalen, Peep F. M. Stalmeier, Lia C.G. Verhoef, Josette E. H. M. Hoekstra‐Weebers, Jan C. Oosterwijk, Nicoline Hoogerbrugge, Ute Moog, W.A.J. van Daal

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation

    Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation by Mariëlle S. van Roosmalen, Peep F. M. Stalmeier, Lia C.G. Verhoef, Josette E. H. M. Hoekstra‐Weebers, Jan C. Oosterwijk, Nicoline Hoogerbrugge, Ute Moog, W.A.J. van Daal

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Reirradiation of head and neck cancer: Long‐term disease control and toxicity

    Reirradiation of head and neck cancer: Long‐term disease control and toxicity by Wouter Bots, Sven van den Bosch, Ellen M. Zwijnenburg, Tim Dijkema, Guido B. van den Broek, Willem L. J. Weijs, Lia C.G. Verhoef, J.H.A.M. Kaanders

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study

    Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts)... by F. Cavalli, Jie Jin, Halyna Pylypenko, G. Verhoef, Noppadol Siritanaratkul, Johannes Drach, Markus Raderer, Jiřı́ Mayer, Juliana Pereira, Gayane Tumyan, Rumiko Okamoto, Susumu Nakahara, Peter Hu, Carlos Appiani, Sepideh Nemat, Tadeusz Robak

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial

    Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial by P. Sonneveld, Bronno van der Holt, Christine M. Segeren, Edo Vellenga, Alexandra Croockewit, G. Verhoef, Jan J. Cornelissen, M Schaafsma, Marinus H. J. van Oers, P. W. Wijermans, Petra H.M. Westveer, H M Lokhorst

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder

    The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder by Daan Dierickx, Thomas Tousseyn, Annelies Requilé, Raf Verscuren, Xavier Sagaert, Julie Morscio, Iwona Włodarska, An Herreman, Dirk Kuypers, Johan Van Cleemput, F. Nevens, Lieven Dupont, Anne Uyttebroeck, Jacques Pirenne, C. De Wolf‐Peeters, G. Verhoef, Lieselot Brepoels, Olivier Gheysens

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

    Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma by M. Dreyling, Franck Morschhauser, Krimo Bouabdallah, Dominique Bron, David Cunningham, Sarit Assouline, G. Verhoef, Kim Linton, Catherine Thiéblemont, Umberto Vitolo, Florian Hiemeyer, Marius Giurescu, J. Garcia‐Vargas, Igor Gorbatchevsky, Li Liu, Karl Koechert, Carol Peña, Manoel Martins das Neves, B.H. Childs, Pier Luigi Zinzani

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma

    Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma by Christine M. Segeren, Pieter Sonneveld, Bronno van der Holt, Joke W. Baars, Douwe H. Biesma, J. J. Cornellissen, Alexandra Croockewit, A. W. Dekker, W.E. Fibbe, Bob Löwenberg, Marinus van Marwijk Kooy, Marinus H. J. van Oers, D. J. Richel, Harry C. Schouten, Edo Vellenga, G. Verhoef, P. Wijermans, S. Wittebol, H M Lokhorst

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Stromal Gene Signatures in Large-B-Cell Lymphomas

    Stromal Gene Signatures in Large-B-Cell Lymphomas by Georg Lenz, George W. Wright, Sandeep S. Davé, Wenming Xiao, John Powell, Hong Zhao, Weihong Xu, Bruce K. Tan, Neta Goldschmidt, Javeed Iqbal, Julie Vose, M. Bast, Kai Fu, DD Weisenburger, Timothy C. Greiner, Jamés O. Armitage, Alastair H. Kyle, Lorraine F. May, Randy D. Gascoyne, Joseph M. Connors, Gunhild Trøen, Harald Holte, Stein Kvaløy, Daan Dierickx, G. Verhoef, Jan Delabie, Erlend B. Smeland, Pedro Jares, Antonio Martı́nez, Armando López‐Guillermo, Emili Montserrat, Elı́as Campo, Rita M. Braziel, Thomas P. Miller, Lisa M. Rimsza, James R. Cook, Brad Pohlman, John Sweetenham, Raymond R. Tubbs, Richard I. Fisher, Elena Hartmann, Andreas Rosenwald, German Ott, Müller-Hermelink Hk, David Wrench, T. Lister, Elaine S. Jaffe, Wyndham H. Wilson, Wing C. Chan, Louis M. Staudt

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: